Glimepiride (brand name Amaryl) is a third-generation sulfonylurea that lowers A1C by about 1 to 1.5 percent through stimulating insulin release from the pancreas. Compared to older sulfonylureas, it offers once-daily convenience, slightly lower hypoglycemia risk than glyburide, and a wide dose range from 1 to 8 mg. The drug remains popular as an add-on to metformin in cost-conscious type 2 diabetes care, though the ADA Standards of Care now prefer GLP-1 agonists or SGLT2 inhibitors when affordable.
How Glimepiride Works
Glimepiride binds the SUR1 receptor on pancreatic beta cells. This closes ATP-sensitive potassium channels, depolarizes the cell, opens calcium channels, and stimulates insulin secretion. Lab studies suggest glimepiride binds and dissociates from SUR1 differently than glyburide, which may explain modest reductions in hypoglycemia rates seen in some comparisons.
- Drug class: third-generation sulfonylurea
- Brand name: Amaryl
- Generic status: yes, widely available
- Onset: within 2 to 3 hours
- Half-life: 5 to 9 hours; effects persist 24 hours
- Metabolism: hepatic (CYP2C9), with a weakly active M1 metabolite
- Excretion: 60 percent renal, 40 percent fecal
Approved Uses
- Adjunct to diet and exercise in adults with type 2 diabetes
- Combination with metformin, GLP-1 agonists, DPP-4 inhibitors, SGLT2 inhibitors, or insulin
- Not used in type 1 diabetes, diabetic ketoacidosis, or pregnancy
Typical Dosing
| Population | Starting Dose | Maintenance | Maximum |
|---|---|---|---|
| Most adults | 1 to 2 mg once daily | 1 to 4 mg | 8 mg/day |
| Older adults or low fasting glucose | 1 mg once daily | 1 to 2 mg | Titrate slowly |
| With insulin | 8 mg once daily plus low-dose insulin | Adjust insulin first | 8 mg |
| Renal impairment | 1 mg once daily | Cautious titration | Reduced based on response |
Doses titrate up by 1 to 2 mg every 1 to 2 weeks based on fasting glucose. Take with breakfast.
Effect on A1C
- A1C reduction: 1.0 to 1.5 percent on average
- Fasting glucose: 30 to 60 mg/dL reduction
- Full effect: 8 to 12 weeks at a stable dose
- Dose-response plateaus above 4 mg in most patients
Common Side Effects
- Hypoglycemia — sweating, shakiness, hunger, palpitations, headache, confusion; can be severe but generally less prolonged than glyburide
- Weight gain — 2 to 4 kg typical first year
- Nausea, abdominal fullness, diarrhea
- Dizziness, headache
- Visual changes early in treatment as glucose normalizes
Serious but Less Common Side Effects
- Severe or prolonged hypoglycemia, especially in older adults, renal impairment, or with alcohol
- Hepatotoxicity — elevated liver enzymes, rarely hepatitis or jaundice
- Hemolytic anemia in G6PD deficiency
- Skin rashes including photosensitivity
- Hyponatremia
- Hypersensitivity reactions (rare)
Drug Interactions
- CYP2C9 inhibitors (fluconazole, amiodarone, sulfa antibiotics) — raise glimepiride levels
- Beta-blockers — mask hypoglycemia symptoms
- NSAIDs, salicylates — augment hypoglycemic effect
- Warfarin — protein-binding shifts
- Corticosteroids, thiazides, atypical antipsychotics — raise glucose, may need dose increase
- Colesevelam — separate by 4 hours (reduces absorption)
- Alcohol — both raises hypoglycemia risk and rarely causes flushing reactions
Glimepiride Compared with Other Sulfonylureas
| Feature | Glimepiride | Glipizide | Glyburide |
|---|---|---|---|
| Generation | 3rd | 2nd | 2nd |
| Dosing frequency | Once daily | Once or twice daily (IR), once daily (XL) | Once or twice daily |
| A1C drop | 1.0 to 1.5% | 1.0 to 1.5% | 1.0 to 1.5% |
| Hypoglycemia | Moderate | Moderate | Highest in class |
| Weight gain | 2 to 4 kg | 2 to 5 kg | 3 to 5 kg |
| Older adults | Acceptable with caution | Preferred SU | Beers criteria — avoid |
| Cost/month | ~$4 to $15 | ~$4 to $15 | ~$4 to $15 |
What the ADVANCE Trial Showed
The ADVANCE trial (Patel et al., NEJM 2008) randomized 11,140 patients with type 2 diabetes to intensive glucose control built around gliclazide MR — a third-generation sulfonylurea not approved in the US but pharmacologically similar to glimepiride. The intensive arm achieved a median A1C of 6.5 percent versus 7.3 percent in standard care. Major macrovascular events were not significantly reduced, but a composite of major macrovascular and microvascular events fell by 10 percent, driven largely by reduced nephropathy. Severe hypoglycemia was higher in the intensive arm, though rates were lower than seen with glyburide-based regimens in earlier trials. The lesson: third-generation sulfonylureas can deliver durable glucose lowering with hypoglycemia rates that are real but manageable.
Where Glimepiride Fits in 2024 Care
The ADA Standards of Care 2024 position metformin plus GLP-1 agonists or SGLT2 inhibitors as preferred first-line therapy, especially in patients with cardiovascular disease, heart failure, or chronic kidney disease. Sulfonylureas such as glimepiride are used:
- When cost limits access to newer drug classes
- As add-on to metformin in patients without significant CV or renal indications for the newer classes
- In combination regimens where one more inexpensive A1C-lowering agent is needed
Who Should Be Cautious or Avoid Glimepiride
- Adults at high fall risk or with cognitive impairment
- Significant kidney disease (eGFR <30 mL/min)
- Liver disease
- Sulfonylurea or severe sulfonamide allergy
- Frequent meal-skippers, irregular eaters
- Heavy alcohol use
- Pregnancy and breastfeeding
- G6PD deficiency (relative caution)
Living with Glimepiride
- Take with breakfast every day at the same time
- Always eat the meal that follows the dose
- Carry fast-acting glucose (glucose tablets, juice)
- Teach a household member the rule of 15 — 15 g of carbohydrate, recheck in 15 minutes
- Test glucose often during titration and after dose changes
- Wear medical ID
- Tell every clinician about your sulfonylurea before new prescriptions or procedures
Related Reading
See our companion guides on glipizide, glyburide, the sulfonylureas list, and class-level sulfonylureas side effects. The A1C levels overview helps in setting your A1C target with your clinician.
The Bottom Line
Glimepiride is a reasonable, inexpensive option within the sulfonylurea class. It lowers A1C by 1 to 1.5 percent on once-daily dosing, with hypoglycemia and weight gain that are real but typically less severe than with glyburide. Most modern guidelines favor metformin first, then GLP-1 agonists or SGLT2 inhibitors when affordable, with glimepiride or glipizide reserved as cost-conscious add-on options. Older adults, people with kidney disease, heavy alcohol drinkers, and irregular eaters should be careful or look at other classes. Talk to your clinician about whether glimepiride is the right next step for your specific situation.
